Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Inclusion Criteria:

• Pathologically documented, locally advanced or metastatic solid tumor with a KRASG12D-mutation

• Received and progressed or been intolerant to prior standard therapy (includingtargeted therapy) appropriate for tumor type and stage

• ECOG performance status 0 or 1

• Adequate organ function

Exclusion Criteria:

• Primary central nervous system (CNS) tumors

• Known or suspected leptomeningeal or active brain metastases or spinal cordcompression

• Known or suspected impairment of gastrointestinal function that may prohibit abilityto swallow or absorb an oral medication

• Participant was previously treated with an investigational KRAS G12D inhibitor, pan-or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

Other inclusion/exclusion criteria may apply.